Report Date: July 16, 2026 (after market close) | Call: 4:30 PM ET
ISRG has had a rough 2026 despite fundamentally solid operating results. The stock closed the July 14 session down sharply, with shares down more than 25% year-to-date and off over 30% from their 52-week high before this print. Options markets are pricing roughly a 7% one-day move around tomorrow's release, with the stock trading at a premium ~48-50x trailing P/E even after the pullback.
The sell-off has been more about sentiment, valuation compression, and emerging risk narratives (competition, tariffs, a component recall, and slowing international markets) than about a broken growth story — Q1 was actually a beat-and-raise quarter. That disconnect is exactly what makes tomorrow's report a key sentiment reset point.
Intuitive's first quarter, reported April 21, was strong across the board:
Off that strong quarter, the stock has still fallen — underscoring that the market is discounting risks well beyond the current numbers.
1. Procedure growth cadence and geographic mix. Q1 growth (17% total, 16% da Vinci) ran ahead of the raised full-year guide, so the market will want to see whether that pace held into Q2 or decelerated toward the guided range. Key swing factors flagged by management: continued weakness in China (low tender activity, domestic competition, policy-driven pricing pressure, with clarity on new reimbursement not expected until 2027) and Japan (soft capital placements, though new MHLW reimbursement for seven additional procedures and high-volume program support took effect in June 2026). U.S. strength in general surgery, after-hours utilization, and non-hysterectomy gynecology procedures should continue, while GLP-1-driven weakness in bariatric procedures (down ~10% in Q1) is a persistent headwind analysts are watching.
2. da Vinci 5 placement pace and utilization. Da Vinci 5 utilization is running about 11% above the legacy Xi platform, and the upgrade/trade-in cycle (119 trade-ins in Q1 vs. 67 a year ago) has been a bigger-than-expected tailwind for systems revenue and pricing. Faster-than-expected da Vinci 5 adoption is one of the more likely sources of an upside surprise in placements and guidance.
3. Margins vs. tariffs and input costs. Management guided to higher oil, freight, and semiconductor memory costs weighing more heavily on gross margin in the back half of the year even as tariff impact assumptions were trimmed to ~100bps. Watch for commentary on whether cost inflation is tracking as expected and whether da Vinci 5 and Ion contribution margins (already comparable to Xi and near corporate average, respectively) continue to improve.
4. Instrument/recall overhang. A voluntary Class II recall tied to certain da Vinci components has drawn fresh scrutiny of product-quality controls, since instruments and accessories are the highest-margin, most recurring piece of the revenue model. Any update on scope, remediation costs, or customer impact will be closely parsed.
5. Competitive and legal noise. Sell-side commentary ahead of the print has repeatedly cited competition (including Chinese domestic robotic players gaining tender share and newer entrants like J&J's Ottava and CMR Surgical's Versius Plus), remanufactured/third-party instrument dynamics, and valuation as reasons for trimmed price targets — TD Cowen and RBC Capital both cut targets this week (RBC to $600 from $650) while maintaining bullish ratings, and Evercore ISI cut its target to $430 while staying "In Line." None of this reflects a change in Intuitive's near-term numbers, but it frames why multiple compression has outpaced fundamentals.
6. SP platform and pipeline updates. SP procedure growth ran at 68% in Q1, and the SP stapler moved into broad U.S. launch. Watch for progress on international staple rollout (Korea, Europe), new indications (e.g., nipple-sparing mastectomy), and any timing color on Ion's ROSE/EBUS integration or lung-cancer staging ambitions.
Wall Street is looking for roughly $2.81–2.82 billion in revenue and ~$2.48–2.50 non-GAAP EPS, implying growth of roughly 14–16% year-over-year on both lines — a deceleration from Q1's 23%/38% pace, consistent with tougher comps and the full-year guidance range. Intuitive has beaten consensus EPS in each of the last four quarters (by double-digit percentages in several), so the bar, while raised, has historically proven beatable.
Fundamentally, Intuitive continues to execute: procedure growth is running at or above the top of its raised guidance range, da Vinci 5 is driving an accretive pricing and trade-in cycle, gross margins are expanding despite tariffs, and international penetration keeps climbing (OUS now ~38% of da Vinci volume, up from 25% a decade ago). The stock's 2026 drawdown looks driven more by valuation reset, competitive fear (especially China), GLP-1/bariatric headwinds, and a fresh instrument recall than by a fundamental break in the growth algorithm. Tomorrow's print is less about whether the business is healthy — Q1 already answered that — and more about whether management can reassure investors on China/Japan trajectory, tariff/cost inflation, and the recall's financial scope, which will determine whether the multiple can stabilize or compress further.